Genfit Gestione

Gestione criteri di controllo 3/4

Genfit Il CEO è M. Prigent, nominato in Sep2019, e ha un mandato di 5.17 anni. la retribuzione annua totale è € 664.22K, composta da 59.3% di stipendio e 40.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.062% delle azioni della società, per un valore di € 127.58K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 7.4 anni.

Informazioni chiave

M. Prigent

Amministratore delegato

€664.2k

Compenso totale

Percentuale dello stipendio del CEO	59.3%
Mandato del CEO	5.2yrs
Proprietà del CEO	0.06%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	7.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Nov 16

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 26

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Sep 24

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Sep 22

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di M. Prigent rispetto agli utili di Genfit?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€22m
Mar 31 2024	n/a	n/a	-€3m
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

Compensazione vs Mercato: La retribuzione totale di M. ($USD 699.26K ) è superiore alla media delle aziende di dimensioni simili nel mercato French ($USD 485.20K ).

Compensazione vs guadagni: La retribuzione di M. è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

M. Prigent (55 yo)

5.2yrs

Mandato

€664,224

Compensazione

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.4yrs	€359.01k	0.094% € 193.6k
M. Prigent	Chief Executive Officer	5.2yrs	€664.22k	0.062% € 127.6k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Thomas Baetz	Chief Financial Officer	3.6yrs	Nessun dato	Nessun dato
Pascal Caisey	Chief Operating Officer	2.7yrs	Nessun dato	0.0095% € 19.6k
Meriam Kabbaj	Chief Technology Officer	1.9yrs	Nessun dato	Nessun dato
Dean Hum	Chief Scientific Officer	2.8yrs	€795.03k	0.021% € 42.8k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.7yrs	Nessun dato	0.0094% € 19.4k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.8yrs	Nessun dato	0.023% € 46.7k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.7yrs	Nessun dato	0.0055% € 11.5k
Emilie Desodt	Executive Vice President of Human Resources	2.7yrs	Nessun dato	0.0035% € 7.2k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.6yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di GNFT è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.4yrs	€359.01k	0.094% € 193.6k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Philippe Moons	Board Observer	3.8yrs	€7.63k	0.0021% € 4.3k
Florence Séjourné	Director	7.4yrs	Nessun dato	Nessun dato
Scott L. Friedman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Arun Sanyal	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Trauner	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Catherine Larue	Independent Director	7.4yrs	€43.60k	Nessun dato
Vlad Ratziu	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anne-Helene Monsellato	Independent Director	7.4yrs	€39.24k	Nessun dato
Katherine Kalin	Independent Director	4.3yrs	€39.24k	0.010% € 20.8k
Eric Baclet	Independent Vice-Chairman of the Board	4.3yrs	€47.96k	0.0024% € 5.0k

7.4yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GNFT sono considerati esperti (durata media dell'incarico 7.4 anni).

Genfit Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Investor sentiment deteriorates as stock falls 20%

Consensus EPS estimates increase by 21%, revenue downgraded

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Investor sentiment improves as stock rises 26%

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

First half 2024 earnings: EPS and revenues exceed analyst expectations

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Price target raised to €8.20

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.20

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT